Sarah Cannon Research Institute Presents 74 Abstracts at the American Society of Clinical Oncology's 50th Annual Meeting
NASHVILLE, TN, May 22, 2014 – Sarah Cannon Research Institute (SCRI) announced today that the American Society for Clinical Oncology (ASCO®) has selected 74 abstracts authored by SCRI investigators for presentation at its 50th annual meeting. The meeting, which will be held in Chicago May 30 - June 3, brings together more than 25,000 oncology professionals from a broad range of specialties to discuss this year’s theme, “Science and Society.”
Accepted presentations from SCRI include 14 oral abstracts, of which six are in clinical science symposiums, as well as 21 poster highlights and 39 general posters. Additionally, 10 abstracts were selected for publication.
“Sharing the latest in cancer research, to discuss and debate the highlights with our oncology peers and to take the findings home for further study and improvement, is what makes the ASCO® Annual Meeting such an important forum,” said Dee Anna Smith, SCRI CEO. “Our growing contributions to this meeting demonstrate how our investigators are continuing to change the way cancer is treated by identifying more targeted and effective therapies for our patients.”During this meeting, David R. Spigel, MD, SCRI’s Director of Lung Cancer Research, will deliver an oral presentation highlighting the results from a pivotal Phase III randomized, multicenter, placebo-controlled, global trial evaluating onartuzumab + erlotinib versus erlotinib in previously treated stage IIIb or IV patients with non-small-cell metastatic lung cancer.
In addition, SCRI’s Chief Medical Officer, Howard A. Burris III, MD, will give an oral presentation on the Phase I study of DNIB0600A, an antibody-drug conjugate targeting NaPi2b in patients with non-small-cell lung cancer or platinum resistant ovarian cancer.
“Developing novel cancer therapies continues to be the focus of SCRI as we strive to meet the needs and improve the outcomes of our patients,” Burris said. “We are looking forward to sharing the latest information from many of our ongoing trials at ASCO® this year.”
Other SCRI investigators will present research updates at the annual meeting, including: Hendrik-Tobias Arkenau, MD, PhD, Todd M. Bauer, MD, Johanna C. Bendell, MD, Jesus G. Berdeja, MD, Ian W Flinn, MD, PhD, John D. Hainsworth, MD, Erika P. Hamilton, MD, Jeffrey R. Infante, MD, Andrew S. Kennedy, MD, Suzanne F. Jones, PharmD, Zeqiang Ma, PhD, Kent C. Shih, MD, and Denise A. Yardley, MD.Several of SCRI’s partnering investigators will also be contributing to the meeting from the following strategic research sites: Tennessee Oncology, Florida Cancer Specialists, The Center for Blood and Cancer Disorders – Ft. Worth, and Oncology Hematology Care, Inc.
About Sarah Cannon Research Institute
Sarah Cannon Research Institute (SCRI) is one of the world’s leading oncology research organizations conducting community-based clinical trials. In 2022, SCRI formed a joint venture with former US Oncology Research to enhance clinical trial access and availability across the country. Focused on advancing therapies for patients over the last three decades, SCRI is a leader in drug development. It has conducted more than 600 first-in-human clinical trials since its inception and contributed to pivotal research that has led to the majority of new cancer therapies approved by the FDA today. The combined research network brings together physicians who are actively accruing patients to clinical trials at more than 250 locations in 26 states across the US. Please click here to earn more about our research offerings.